Journal article 859 views 188 downloads
Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK
Natasha Shrikrishnapalasuriyar,
Ayesha Shaikh,
Aliya Mohd Ruslan,
Giselle Sharaf,
Maneesh Udiawar,
David E. Price,
Jeffrey Stephens 
Diabetes & Metabolic Syndrome: Clinical Research & Reviews, Volume: 14, Issue: 3, Pages: 237 - 239
Swansea University Author:
Jeffrey Stephens
-
PDF | Accepted Manuscript
Released under the terms of a Creative Commons Attribution Non-Commercial No Derivatives License (CC-BY-NC-ND).
Download (123.77KB)
DOI (Published version): 10.1016/j.dsx.2020.03.007
Abstract
Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK
| Published in: | Diabetes & Metabolic Syndrome: Clinical Research & Reviews |
|---|---|
| ISSN: | 1871-4021 |
| Published: |
Elsevier BV
2020
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa53936 |
| Keywords: |
Dapagliflozin; SGLT2 inhibitor; HbA1c; Cardiovascular |
|---|---|
| Issue: |
3 |
| Start Page: |
237 |
| End Page: |
239 |